Dimethyl fumarate has been found to normalize the expression of the friedreich ataxia gene. However, its effectiveness in improving cardiac function in friedreich's ataxia is unclear, with one study suggesting that omaveloxolone, not dimethyl fumarate, may be beneficial for this purpose. The potential applications of dimethyl fumarate are being explored, but its role in treating friedreich's ataxia and other conditions remains a subject of ongoing research.